Policy | May 25, 2021
Cipla to market Roche's Antibody Cocktail in India
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The product patent has been already filed under fast track approval
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The agreement will help ensure wider reach and access to patients in India
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
